New Horizon Health Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部分內容所產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 諾輝健康 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6606） 獨 立 非 執 行 董 事 辭 任； 遵守上市規則第3.10(1)條、第3.25條、第3.27A條及第13.92(2)條； 及 繼續暫停買賣 獨立非執行董事辭任 遵守上市規則第3.10(1)條、第3.25條、第3.27A條及第13.92(2)條 根 據 聯 交 所 證 券 上 市 規 則（「上市規則」）第3.10(1)條、第3.25條及第3.27A條， (i)董 事 會 必 須 包 括 至 少 三 名 獨 立 非 執 行 董 事；(ii)薪酬委員會須由一名獨 立 非 執 行 董 事 擔 任 主 席，且 成 員 須 以 獨 立 非 執 行 董 事 佔 大 多 數；及(iii)提 名 委 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 證券代號 (如上市) | 06606 | 說明 | 普通股 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.00005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.00005 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 | 截至月份: | 2025年7月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 諾輝健康 | ...

Core Viewpoint - Nohui Health (06606) has officially filed for the appointment of joint provisional liquidators in the Grand Court on July 8, 2025, to protect the interests of shareholders [1] Group 1 - The hearing for the joint provisional liquidators' application is scheduled for August 6, 2025, at 10 AM (Cayman time) [1] - The appointment of joint provisional liquidators aims to hand over the company's business and affairs to independent court professionals [1] - The joint provisional liquidators will continue to investigate matters mentioned in the announcements dated March 28, 2024, and May 28, 2024, and explore potential restructuring plans [1] Group 2 - The company remains suspended from trading [1]

委任共同临时清盘人是为了将公司的业务和事务交予独立的法院专业人员以维持和保护公司股东的利 益。共同临时清盘人一经委任，将会继续就公司2024年3月28日及2024年5月28日公告中提及的事项进行 调查，并且探索潜在的重组方案。 智通财经APP讯，诺辉健康(06606)发布公告，公司已于2025年7月8日(开曼时间)正式向大法院立案共同 临时清盘人申请及呈请。共同临时清盘人申请的聆讯将于2025年8月6日(开曼时间)上午10时在大法院进 行。 此外，继续停牌。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部分內容所產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 茲提述本公司日期為2025年7月4日 之 公 告（「公 告」）。 New Horizon Health Limited 諾輝健康 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6606） 內 幕 消 息：委 任 共 同 臨 時 清 盤 人 申 請 本 公 告 由 諾 輝 健 康（「本公司」或「公 司」，連 同 其 附 屬 公 司 及 合 併 聯 屬 實 體，統 稱「本集團」或「集 團」）根 據 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）證 券 上 市 規 則（「上市規則」）第13.09(2)(a)條及第13.24A條，及 證 券 及 期 貨 條 例 （香 港 法 例 第571章）第XIVA部 項 下 之 內 幕 消 息 條 文（定 義 見 上 市 規 則）而 作 出。 本公司股份已自2024 ...

Group 1 - The core viewpoint is that several fund companies have collectively downgraded the valuation of the Hong Kong-listed company NuoHui Health, with some estimates dropping by over 90% from the pre-suspension price of 14.14 HKD to as low as 1.2 HKD [1] - On June 26, Bosera Fund announced a valuation of 3.33 HKD per share for NuoHui Health, while Great Wall Fund set its valuation at 1.2 HKD per share, indicating a significant reduction in perceived value [1] - NuoHui Health has been suspended since March 2024 due to allegations of financial fraud and audit concerns, leading to multiple valuation downgrades by various fund companies [1] Group 2 - In addition to NuoHui Health, the A-share market's ST Zitian also faced valuation downgrades, with Huaxia Fund reducing its valuation from 8.74 CNY to 2.5 CNY, reflecting a decline of over 70% [3] - The stringent valuation adjustments by fund companies for NuoHui Health and ST Zitian are attributed to financial uncertainties and operational risks, highlighting a trend of increasing risk management standards within the public fund industry [3] - Fund managers are reportedly becoming more selective about investment targets, with a stronger emphasis on company fundamentals, particularly avoiding ST stocks [3]

Core Viewpoint - Changcheng Fund has lowered the valuation of Nohow Health to HKD 1.20 per share, representing a 91.51% decrease from the price before suspension [1] Group 1: Valuation Adjustments - This is the second time Changcheng Fund has adjusted its valuation for Nohow Health, following a previous adjustment to HKD 7.48 per share in July of last year [1] - Multiple fund companies have adjusted their valuations for Nohow Health since mid-last year, indicating a pessimistic outlook on its resumption prospects [1] Group 2: Industry Context - Nohow Health, once known as the "first stock for cancer early screening," has seen its valuation approach zero recently, highlighting potential compliance risks hidden beneath the high growth narrative of biotech companies [1]

Group 1 - The cancer prevention and treatment situation in China remains severe, with 4.82 million new cancer cases and 2.57 million deaths reported in 2022, indicating a diagnosis every minute and a death every 15 seconds [1] - The top five cancers in terms of new cases are lung cancer, colorectal cancer, thyroid cancer, liver cancer, and stomach cancer, which together account for 57.42% of new cases, highlighting key areas for cancer prevention [1] - Early detection significantly improves cure rates for cancers, particularly colorectal cancer, where the five-year survival rate is 91.8% if detected early, but drops to 10.8% if treatment is delayed [1] Group 2 - Nohui Health's Changweiqing is a non-invasive colorectal cancer screening product that requires only a stool sample, utilizing triple detection technology with a negative predictive value of 99.6% [3] - All commercialized products from Nohui Health are supported by extensive clinical data, ensuring their professionalism, compliance, reliability, and high recognition [3] - Changweiqing is the only product included in all national colorectal cancer screening and treatment guidelines in China, underscoring its significance in the market [3]

Financial Performance - New Horizon Health reported a revenue of HKD 150 million for the first half of 2023, representing a 25% increase compared to the same period in 2022[1]. - The company has set a performance guidance of HKD 350 million in revenue for the full year 2023, representing a 20% year-over-year growth[1]. - For the six months ended June 30, 2023, revenue was RMB 822.7 million, an increase of 264.6% compared to RMB 225.7 million for the same period in 2022[19]. - The company reported a net loss of HKD 10 million for the first half of 2023, an improvement from a loss of HKD 15 million in the same period last year[1]. - Adjusted net profit for the six months was RMB 61.3 million, a significant improvement from an adjusted net loss of RMB 106.2 million in the same period last year[19]. - The company reported a net profit of RMB 125,343 thousand for the six months ended June 30, 2023, compared to a net loss of RMB 65,282 thousand in the prior year[197]. - The total comprehensive income for the first half of 2023 was RMB 127,519 thousand, compared to a loss in the previous period, marking a turnaround in performance[200]. Gross Profit and Margins - The company achieved a gross profit margin of 65%, up from 60% in the previous year, indicating improved operational efficiency[1]. - Gross profit for the same period was RMB 747.5 million with a gross margin of 90.9%, up from RMB 185.1 million and 82.0% in the prior year[19]. - The gross margin improved to 90.9%, up approximately 890 basis points from 82.0% in the same period last year[56]. User Growth and Market Expansion - User data showed a 30% increase in the number of active users, reaching 200,000 by June 30, 2023[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[1]. - The company aims to increase market penetration of its products, including Changweiqing and Pupu Tube, leveraging its unique position as the only approved molecular cancer screening test in China[89]. Research and Development - Research and development expenses increased by 20% to HKD 30 million, reflecting the company's commitment to innovation[1]. - R&D expenses for the six months ended June 30, 2023, were RMB 63.6 million, a 61.4% increase from RMB 39.4 million in the same period of 2022[21]. - The company established a R&D center in Hong Kong in January 2023, focusing on cancer screening pipeline development[24]. - The company has established a strong R&D team, with over 73.0% of members holding master's or doctoral degrees, led by the Chief Scientific Officer and Chief Technology Officer[41]. Product Development and Launches - New product launches include the "宫证清 IVD" and "常卫清 IVD," which are expected to contribute an additional HKD 50 million in revenue in the next fiscal year[1]. - The flagship product, 常卫清, generated revenue of approximately RMB 490.5 million, a 566.2% increase from RMB 73.6 million year-over-year[21]. - The company has four self-developed cancer screening tests, with the latest, 宮证清, commercialized in Hong Kong in May 2023[45]. Strategic Partnerships and Acquisitions - The management emphasized a focus on strategic partnerships to drive growth and enhance customer engagement moving forward[1]. - New Horizon Health is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of HKD 100 million allocated for this purpose[1]. - The company has formed strategic partnerships with major players like AstraZeneca and Prenetics to enhance market penetration and awareness of colorectal cancer screening[45]. Financial Position and Cash Flow - Cash and cash equivalents as of June 30, 2023, were RMB 2,047.0 million, a 24.1% increase from RMB 1,648.9 million at the end of 2022[21]. - The company’s total liabilities increased to RMB 265,484 thousand from RMB 227,433 thousand, indicating a rise of 16.7%[198]. - The company’s total equity reached RMB 2,985,885 thousand as of June 30, 2023, compared to RMB 2,121,650 thousand at the end of 2022, reflecting a growth of about 41%[199]. Market Trends and Future Outlook - The colorectal cancer screening market in China is expected to grow significantly due to aging population and increased public awareness, with the company’s 常卫清 being the only test capable of detecting precancerous lesions[46]. - The company aims to advance technological innovation and accelerate the adoption of cancer screening technologies in China and globally[26]. - The company plans to enhance cancer screening awareness in China, targeting a 5-year survival rate of at least 46.6% by 2030[86]. Shareholder Information and Equity Incentives - The board has not declared an interim dividend for the six months ending June 30, 2023, consistent with the previous year[97]. - The maximum number of shares that can be delivered under the pre-IPO equity incentive plan is capped at 31,686,768 shares[117]. - The company has established a restricted share unit plan for 2022, which prohibits the board from granting any awards during specific blackout periods related to insider information and financial performance announcements[138].

Financial Performance - For the six months ended June 30, 2023, revenue reached RMB 822.7 million, a significant increase of 264.6% compared to RMB 225.7 million in the same period of 2022[2] - Gross profit for the same period was RMB 747.5 million, with a gross margin of 90.9%, up from RMB 185.1 million and 82.0% in 2022[2] - Adjusted net profit for the six months was RMB 61.3 million, a turnaround from an adjusted net loss of RMB 106.2 million in the same period of 2022, marking the first 12-month adjusted net profit[2] - The company achieved a net profit of RMB 125.3 million under International Financial Reporting Standards, compared to a net loss of RMB 65.3 million in the same period of 2022[3] - For the six months ended June 30, 2023, the company reported a profit attributable to owners of RMB 125,654 thousand, compared to a loss of RMB 65,282 thousand in the same period of 2022, marking a significant turnaround[6] - The company achieved a basic and diluted earnings per share of RMB 0.26, compared to a loss per share of RMB 0.15 in the same period last year[6] Revenue Breakdown - Revenue from Changweiqing in mainland China was RMB 490.5 million, a remarkable increase of 566.2% from RMB 73.6 million in 2022, with a gross margin of 91.5%[2] - Revenue from Pupu Tube was RMB 124.0 million, an increase of 80.9% from RMB 68.5 million in 2022, with a gross margin of 87.2%[2] - Revenue from Youyou Tube was RMB 206.5 million, up 147.4% from RMB 83.5 million in 2022, with a gross margin of 94.2%[2] - The revenue from the main product lines for the six months ended June 30, 2023, was RMB 1,821,236 thousand, a significant increase from RMB 1,157,000 thousand for the same period in 2022, representing a growth of approximately 57.3%[17] - The flagship product, 常卫清, recorded a revenue recognition of approximately 428,700 units, up 354.1% from 94,400 units in the same period of 2022[34] Expenses and Costs - Sales and marketing expenses were RMB 571.2 million, representing 69.4% of revenue, compared to 86% in the previous year[3] - Research and development expenses increased by 61.4% to RMB 63.6 million, accounting for 7.7% of revenue, down from 17% in 2022[3] - Total administrative expenses for the six months ended June 30, 2023, were RMB 10,630 thousand, compared to RMB 6,918 thousand for the same period in 2022, indicating an increase of approximately 53.5%[21] - The total sales cost for the group was RMB 75.2 million for the six months ended June 30, 2023, an increase of 85.3% from RMB 40.6 million in the same period of 2022[56] - Employee costs accounted for 48.1% of total R&D expenses in 2023, rising from 35.3% in 2022, with RMB 359.7 million spent[66] Assets and Financial Position - Cash and cash equivalents, along with specific financial assets, totaled RMB 2,047.0 million, a 24.1% increase from RMB 1,648.9 million in the previous year[3] - Total assets reached RMB 2,858,172 thousand as of June 30, 2023, compared to RMB 2,000,576 thousand at the end of 2022, indicating strong growth in the asset base[8] - The company’s net asset value increased to RMB 2,985,885 thousand as of June 30, 2023, from RMB 2,121,650 thousand at the end of 2022, showcasing improved financial health[10] - The company's debt-to-asset ratio increased to 19% as of June 30, 2023, up from 18% on December 31, 2022[77] Research and Development - The company established a research and development center in Hong Kong in January 2023, focusing on cancer screening technologies to expand into international markets outside mainland China[5] - The company has established a comprehensive cancer screening molecular platform with capabilities in R&D, clinical development, testing operations, and commercialization[35] - The company plans to expand its R&D capabilities and product pipeline, focusing on developing screening tests for various cancer types, including cervical cancer, with a strategic partnership established for commercialization in Hong Kong[82] - The company has a strong internal R&D team, with over 73.0% of members holding master's or doctoral degrees, focusing on advancing clinical products and expanding application ranges[47] Market Strategy and Partnerships - The company aims to advance technological innovation and accelerate the adoption of cancer screening technologies in China and globally[34] - The company has formed strategic partnerships with various organizations, including AstraZeneca, to promote its products in public hospitals and pharmacies in mainland China[50] - The company aims to enhance cancer screening awareness and increase market penetration for its products, including Changweiqing and Pupu Tube, to solidify its leadership in the colorectal cancer screening market in China[80] - The company plans to leverage its unique position as the first and only approved molecular cancer screening test to boost brand recognition and strengthen relationships with key opinion leaders and clinical doctors[81] Compliance and Governance - The company is committed to maintaining high corporate governance standards to protect shareholder interests and enhance business value[85] - The company confirmed that external auditors completed the necessary audit/review procedures in accordance with international auditing standards[100] - The company responded to a report alleging financial data fraud, emphasizing transparency and communication with stakeholders[106] Production and Capacity - The newly established production facility in Hangzhou has an annual capacity to produce 20 million sets of Pupu tubes, 20 million sets of Yuyou tubes, and 5 million sets of Changweiqing, all certified under GMP standards[83] - The company has established laboratory testing facilities in Beijing, Hangzhou, and Guangzhou, with a combined annual testing capacity of 2,000,000 tests[83] Employee Growth - The number of employees in the company's laboratories increased from 75 in 1H 2022 to 140 in 1H 2023, indicating significant growth in operational capacity[104] - Total employee costs for the six months ended June 30, 2023, were approximately RMB 212.8 million, compared to RMB 124.4 million for the same period in 2022[79]